Clinical Trial Update: Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update evaluates whether rituximab can help achieve PCR-negative leukapheresis products in patients with relapsed follicular lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Non-Hodgkins Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30